25 XP   0   0   10

Innate Pharma
Buy, Hold or Sell?

Let's analyse Innate Pharma together

PenkeI guess you are interested in Innate Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Innate Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Innate Pharma

I send you an email if I find something interesting about Innate Pharma.

Quick analysis of Innate Pharma (30 sec.)










What can you expect buying and holding a share of Innate Pharma? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$0.72
Expected worth in 1 year
$-2.13
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-2.85
Return On Investment
-110.5%

For what price can you sell your share?

Current Price per Share
$2.58
Expected price per share
$2.185 - $2.55
How sure are you?
50%

1. Valuation of Innate Pharma (5 min.)




Live pricePrice per Share (EOD)

$2.58

Intrinsic Value Per Share

$-5.12 - $2.47

Total Value Per Share

$-4.40 - $3.19

2. Growth of Innate Pharma (5 min.)




Is Innate Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$58.5m$116.2m-$57.6m-98.4%

How much money is Innate Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$62.8m-$57.1m-$5.7m-9.1%
Net Profit Margin-117.1%-436.0%--

How much money comes from the company's main activities?

3. Financial Health of Innate Pharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#462 / 1031

Most Revenue
#131 / 1031

Most Profit
#994 / 1031

Most Efficient
#658 / 1031

What can you expect buying and holding a share of Innate Pharma? (5 min.)

Welcome investor! Innate Pharma's management wants to use your money to grow the business. In return you get a share of Innate Pharma.

What can you expect buying and holding a share of Innate Pharma?

First you should know what it really means to hold a share of Innate Pharma. And how you can make/lose money.

Speculation

The Price per Share of Innate Pharma is $2.58. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Innate Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Innate Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.72. Based on the TTM, the Book Value Change Per Share is $-0.71 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.65 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Innate Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.78-30.1%-0.78-30.1%-0.71-27.4%-0.52-20.0%-0.34-13.4%
Usd Book Value Change Per Share-0.71-27.6%-0.71-27.6%-0.65-25.2%-0.09-3.3%0.041.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.71-27.6%-0.71-27.6%-0.65-25.2%-0.09-3.3%0.041.6%
Usd Price Per Share3.27-3.27-4.35-5.32-7.86-
Price to Earnings Ratio-4.21--4.21--6.16-32.90--13.32-
Price-to-Total Gains Ratio-4.59--4.59--6.70-0.19--226.86-
Price to Book Ratio4.51-4.51-3.03-3.10-7.12-
Price-to-Total Gains Ratio-4.59--4.59--6.70-0.19--226.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.58
Number of shares387
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.71-0.09
Usd Total Gains Per Share-0.71-0.09
Gains per Quarter (387 shares)-275.94-32.94
Gains per Year (387 shares)-1,103.77-131.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1104-11140-132-142
20-2208-22180-264-274
30-3311-33220-395-406
40-4415-44260-527-538
50-5519-55300-659-670
60-6623-66340-791-802
70-7726-77380-922-934
80-8830-88420-1054-1066
90-9934-99460-1186-1198
100-11038-110500-1318-1330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.08.00.020.0%2.016.00.011.1%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%8.010.00.044.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%2.00.016.011.1%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%8.010.00.044.4%

Fundamentals of Innate Pharma

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Fundamental data was last updated by Penke on 2024-03-10 07:16:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Innate Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Innate Pharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Net Profit Margin of -117.1% means that $-1.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Innate Pharma:

  • The MRQ is -117.1%. The company is making a huge loss. -2
  • The TTM is -117.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-117.1%TTM-117.1%0.0%
TTM-117.1%YOY-436.0%+319.0%
TTM-117.1%5Y-138.4%+21.3%
5Y-138.4%10Y-304.4%+166.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-117.1%-159.2%+42.1%
TTM-117.1%-202.3%+85.2%
YOY-436.0%-263.0%-173.0%
5Y-138.4%-452.4%+314.0%
10Y-304.4%-589.0%+284.6%
1.1.2. Return on Assets

Shows how efficient Innate Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • -28.0% Return on Assets means that Innate Pharma generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Innate Pharma:

  • The MRQ is -28.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.0%TTM-28.0%0.0%
TTM-28.0%YOY-19.7%-8.2%
TTM-28.0%5Y-14.6%-13.4%
5Y-14.6%10Y-11.7%-2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.0%-12.5%-15.5%
TTM-28.0%-12.2%-15.8%
YOY-19.7%-11.2%-8.5%
5Y-14.6%-13.3%-1.3%
10Y-11.7%-14.6%+2.9%
1.1.3. Return on Equity

Shows how efficient Innate Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • -107.3% Return on Equity means Innate Pharma generated $-1.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Innate Pharma:

  • The MRQ is -107.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -107.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-107.3%TTM-107.3%0.0%
TTM-107.3%YOY-49.2%-58.1%
TTM-107.3%5Y-41.0%-66.3%
5Y-41.0%10Y-29.0%-12.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-107.3%-16.0%-91.3%
TTM-107.3%-15.8%-91.5%
YOY-49.2%-13.9%-35.3%
5Y-41.0%-18.2%-22.8%
10Y-29.0%-19.1%-9.9%

1.2. Operating Efficiency of Innate Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Innate Pharma is operating .

  • Measures how much profit Innate Pharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • An Operating Margin of -23.5% means the company generated $-0.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Innate Pharma:

  • The MRQ is -23.5%. The company is operating very inefficient. -2
  • The TTM is -23.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-23.5%TTM-23.5%0.0%
TTM-23.5%YOY-342.5%+319.0%
TTM-23.5%5Y-84.1%+60.7%
5Y-84.1%10Y-283.9%+199.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.5%-299.5%+276.0%
TTM-23.5%-208.5%+185.0%
YOY-342.5%-280.2%-62.3%
5Y-84.1%-459.9%+375.8%
10Y-283.9%-596.9%+313.0%
1.2.2. Operating Ratio

Measures how efficient Innate Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.37 means that the operating costs are $2.37 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Innate Pharma:

  • The MRQ is 2.372. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.372. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.372TTM2.3720.000
TTM2.372YOY8.829-6.458
TTM2.3725Y3.156-0.784
5Y3.15610Y4.635-1.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3722.817-0.445
TTM2.3723.181-0.809
YOY8.8293.609+5.220
5Y3.1565.554-2.398
10Y4.6357.396-2.761

1.3. Liquidity of Innate Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Innate Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.38 means the company has $3.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Innate Pharma:

  • The MRQ is 3.383. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.383. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.383TTM3.3830.000
TTM3.383YOY1.731+1.652
TTM3.3835Y2.480+0.903
5Y2.48010Y3.414-0.934
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3833.987-0.604
TTM3.3834.440-1.057
YOY1.7315.569-3.838
5Y2.4806.158-3.678
10Y3.4146.492-3.078
1.3.2. Quick Ratio

Measures if Innate Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Quick Ratio of 3.80 means the company can pay off $3.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Innate Pharma:

  • The MRQ is 3.800. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.800. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.800TTM3.8000.000
TTM3.800YOY1.932+1.868
TTM3.8005Y2.694+1.106
5Y2.69410Y3.737-1.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8003.653+0.147
TTM3.8004.158-0.358
YOY1.9325.515-3.583
5Y2.6946.012-3.318
10Y3.7376.206-2.469

1.4. Solvency of Innate Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Innate Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Innate Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Innate Pharma assets are financed with 73.9% credit (debt) and the remaining percentage (100% - 73.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Innate Pharma:

  • The MRQ is 0.739. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.739. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.739TTM0.7390.000
TTM0.739YOY0.598+0.141
TTM0.7395Y0.584+0.156
5Y0.58410Y0.550+0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7390.336+0.403
TTM0.7390.330+0.409
YOY0.5980.267+0.331
5Y0.5840.367+0.217
10Y0.5500.378+0.172
1.4.2. Debt to Equity Ratio

Measures if Innate Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 283.9% means that company has $2.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Innate Pharma:

  • The MRQ is 2.839. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.839. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.839TTM2.8390.000
TTM2.839YOY1.490+1.349
TTM2.8395Y1.569+1.270
5Y1.56910Y1.593-0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8390.376+2.463
TTM2.8390.398+2.441
YOY1.4900.334+1.156
5Y1.5690.431+1.138
10Y1.5930.476+1.117

2. Market Valuation of Innate Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Innate Pharma generates.

  • Above 15 is considered overpriced but always compare Innate Pharma to the Biotechnology industry mean.
  • A PE ratio of -4.21 means the investor is paying $-4.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Innate Pharma:

  • The EOD is -3.319. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.206. Based on the earnings, the company is expensive. -2
  • The TTM is -4.206. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.319MRQ-4.206+0.888
MRQ-4.206TTM-4.2060.000
TTM-4.206YOY-6.156+1.950
TTM-4.2065Y32.897-37.103
5Y32.89710Y-13.321+46.218
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.319-2.697-0.622
MRQ-4.206-2.422-1.784
TTM-4.206-2.709-1.497
YOY-6.156-4.116-2.040
5Y32.897-6.257+39.154
10Y-13.321-6.478-6.843
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Innate Pharma:

  • The EOD is -9.510. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.053. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.053. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.510MRQ-12.053+2.543
MRQ-12.053TTM-12.0530.000
TTM-12.053YOY-5.438-6.615
TTM-12.0535Y-11.335-0.718
5Y-11.33510Y-16.459+5.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.510-3.344-6.166
MRQ-12.053-2.939-9.114
TTM-12.053-3.486-8.567
YOY-5.438-5.592+0.154
5Y-11.335-8.464-2.871
10Y-16.459-8.872-7.587
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Innate Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.51 means the investor is paying $4.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Innate Pharma:

  • The EOD is 3.561. Based on the equity, the company is fair priced.
  • The MRQ is 4.513. Based on the equity, the company is fair priced.
  • The TTM is 4.513. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.561MRQ4.513-0.952
MRQ4.513TTM4.5130.000
TTM4.513YOY3.026+1.487
TTM4.5135Y3.098+1.416
5Y3.09810Y7.124-4.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5612.198+1.363
MRQ4.5132.042+2.471
TTM4.5132.121+2.392
YOY3.0262.907+0.119
5Y3.0983.682-0.584
10Y7.1244.114+3.010
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Innate Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.713-0.7130%-0.649-9%-0.085-88%0.041-1831%
Book Value Per Share--0.7250.7250%1.438-50%1.879-61%1.420-49%
Current Ratio--3.3833.3830%1.731+95%2.480+36%3.414-1%
Debt To Asset Ratio--0.7390.7390%0.598+24%0.584+27%0.550+35%
Debt To Equity Ratio--2.8392.8390%1.490+91%1.569+81%1.593+78%
Dividend Per Share----0%-0%-0%0.001-100%
Eps---0.777-0.7770%-0.707-9%-0.515-34%-0.345-56%
Free Cash Flow Per Share---0.271-0.2710%-0.800+195%-0.556+105%-0.186-31%
Free Cash Flow To Equity Per Share---0.296-0.2960%-0.441+49%-0.120-60%0.126-334%
Gross Profit Margin--1.1371.1370%1.181-4%1.073+6%1.050+8%
Intrinsic Value_10Y_max--2.467--------
Intrinsic Value_10Y_min---5.123--------
Intrinsic Value_1Y_max---0.093--------
Intrinsic Value_1Y_min---0.613--------
Intrinsic Value_3Y_max---0.020--------
Intrinsic Value_3Y_min---1.767--------
Intrinsic Value_5Y_max--0.365--------
Intrinsic Value_5Y_min---2.829--------
Market Cap208572360.000-27%264353340.000264353340.0000%351662700.000-25%430241124.000-39%635240267.600-58%
Net Profit Margin---1.171-1.1710%-4.360+272%-1.384+18%-3.044+160%
Operating Margin---0.235-0.2350%-3.425+1359%-0.841+258%-2.839+1110%
Operating Ratio--2.3722.3720%8.829-73%3.156-25%4.635-49%
Pb Ratio3.561-27%4.5134.5130%3.026+49%3.098+46%7.124-37%
Pe Ratio-3.319+21%-4.206-4.2060%-6.156+46%32.897-113%-13.321+217%
Price Per Share2.580-27%3.2703.2700%4.350-25%5.322-39%7.858-58%
Price To Free Cash Flow Ratio-9.510+21%-12.053-12.0530%-5.438-55%-11.335-6%-16.459+37%
Price To Total Gains Ratio-3.618+21%-4.586-4.5860%-6.698+46%0.193-2477%-226.863+4847%
Quick Ratio--3.8003.8000%1.932+97%2.694+41%3.737+2%
Return On Assets---0.280-0.2800%-0.197-29%-0.146-48%-0.117-58%
Return On Equity---1.073-1.0730%-0.492-54%-0.410-62%-0.290-73%
Total Gains Per Share---0.713-0.7130%-0.649-9%-0.085-88%0.042-1784%
Usd Book Value--58575136.70058575136.7000%116217848.000-50%151918707.480-61%114803633.420-49%
Usd Book Value Change Per Share---0.713-0.7130%-0.649-9%-0.085-88%0.041-1831%
Usd Book Value Per Share--0.7250.7250%1.438-50%1.879-61%1.420-49%
Usd Dividend Per Share----0%-0%-0%0.001-100%
Usd Eps---0.777-0.7770%-0.707-9%-0.515-34%-0.345-56%
Usd Free Cash Flow---21932549.200-21932549.2000%-64671597.900+195%-44909804.260+105%-15066025.770-31%
Usd Free Cash Flow Per Share---0.271-0.2710%-0.800+195%-0.556+105%-0.186-31%
Usd Free Cash Flow To Equity Per Share---0.296-0.2960%-0.441+49%-0.120-60%0.126-334%
Usd Market Cap208572360.000-27%264353340.000264353340.0000%351662700.000-25%430241124.000-39%635240267.600-58%
Usd Price Per Share2.580-27%3.2703.2700%4.350-25%5.322-39%7.858-58%
Usd Profit---62850015.100-62850015.1000%-57123495.300-9%-41668382.040-34%-27864159.320-56%
Usd Revenue--53694506.30053694506.3000%13101550.400+310%57859916.660-7%41918254.740+28%
Usd Total Gains Per Share---0.713-0.7130%-0.649-9%-0.085-88%0.042-1784%
 EOD+3 -5MRQTTM+0 -0YOY+14 -205Y+12 -2210Y+9 -27

3.2. Fundamental Score

Let's check the fundamental score of Innate Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.319
Price to Book Ratio (EOD)Between0-13.561
Net Profit Margin (MRQ)Greater than0-1.171
Operating Margin (MRQ)Greater than0-0.235
Quick Ratio (MRQ)Greater than13.800
Current Ratio (MRQ)Greater than13.383
Debt to Asset Ratio (MRQ)Less than10.739
Debt to Equity Ratio (MRQ)Less than12.839
Return on Equity (MRQ)Greater than0.15-1.073
Return on Assets (MRQ)Greater than0.05-0.280
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Innate Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.100
Ma 20Greater thanMa 502.501
Ma 50Greater thanMa 1002.704
Ma 100Greater thanMa 2002.628
OpenGreater thanClose2.390
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets207,863
Total Liabilities153,712
Total Stockholder Equity54,151
 As reported
Total Liabilities 153,712
Total Stockholder Equity+ 54,151
Total Assets = 207,863

Assets

Total Assets207,863
Total Current Assets139,831
Long-term Assets68,033
Total Current Assets
Cash And Cash Equivalents 84,225
Short-term Investments 17,260
Net Receivables 38,346
Inventory -2
Other Current Assets 2
Total Current Assets  (as reported)139,831
Total Current Assets  (calculated)139,831
+/-0
Long-term Assets
Property Plant Equipment 8,542
Goodwill -40,997
Long Term Investments 35,119
Intangible Assets 42,553
Long-term Assets Other 14,248
Long-term Assets  (as reported)68,033
Long-term Assets  (calculated)59,465
+/- 8,568

Liabilities & Shareholders' Equity

Total Current Liabilities41,338
Long-term Liabilities112,374
Total Stockholder Equity54,151
Total Current Liabilities
Short-term Debt 2,102
Short Long Term Debt 1,263
Accounts payable 20,911
Other Current Liabilities 11,765
Total Current Liabilities  (as reported)41,338
Total Current Liabilities  (calculated)36,041
+/- 5,297
Long-term Liabilities
Capital Lease Obligations 2,059
Other Liabilities 72,225
Long-term Liabilities  (as reported)112,374
Long-term Liabilities  (calculated)74,284
+/- 38,090
Total Stockholder Equity
Common Stock4,011
Retained Earnings -330,316
Accumulated Other Comprehensive Income 819
Other Stockholders Equity 379,637
Total Stockholder Equity (as reported)54,151
Total Stockholder Equity (calculated)54,151
+/-0
Other
Capital Stock4,011
Cash and Short Term Investments 101,485
Common Stock Shares Outstanding 79,640
Current Deferred Revenue6,560
Liabilities and Stockholders Equity 207,863
Net Debt -41,974
Net Invested Capital 54,151
Net Tangible Assets 52,595
Net Working Capital 98,493
Property Plant and Equipment Gross 8,542
Short Long Term Debt Total 42,251



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
> Total Assets 
24,767
69,255
63,153
60,862
64,219
48,010
60,109
48,295
55,882
90,690
305,956
281,577
255,023
451,216
401,361
307,423
267,496
207,863
207,863267,496307,423401,361451,216255,023281,577305,95690,69055,88248,29560,10948,01064,21960,86263,15369,25524,767
   > Total Current Assets 
21,209
64,273
55,595
52,209
56,266
40,664
52,975
40,997
49,350
79,314
252,126
230,078
137,521
319,643
237,605
173,332
138,256
139,831
139,831138,256173,332237,605319,643137,521230,078252,12679,31449,35040,99752,97540,66456,26652,20955,59564,27321,209
       Cash And Cash Equivalents 
2,586
6,159
2,482
10,885
46,448
31,818
46,606
30,584
38,360
64,286
152,870
175,906
99,367
152,314
202,887
136,792
103,756
84,225
84,225103,756136,792202,887152,31499,367175,906152,87064,28638,36030,58446,60631,81846,44810,8852,4826,1592,586
       Short-term Investments 
15,757
53,664
48,301
22,947
2,746
2,763
0
2,032
2,989
4,952
83,040
21,782
16,743
15,217
15,978
14,845
16,080
17,260
17,26016,08014,84515,97815,21716,74321,78283,0404,9522,9892,03202,7632,74622,94748,30153,66415,757
       Net Receivables 
0
0
0
0
7,071
6,083
0
7,229
7,062
8,585
9,948
25,554
15,084
146,637
13,141
21,695
18,420
38,346
38,34618,42021,69513,141146,63715,08425,5549,9488,5857,0627,22906,0837,0710000
       Other Current Assets 
0
0
0
0
1
0
0
1
-1
1
636
513
-1
1,264
-1
7,947
4,946
2
24,9467,947-11,264-15136361-110010000
   > Long-term Assets 
3,558
4,982
7,558
8,653
7,953
7,346
7,134
7,299
6,532
11,377
53,830
51,499
117,501
131,574
163,756
134,091
129,241
68,033
68,033129,241134,091163,756131,574117,50151,49953,83011,3776,5327,2997,1347,3467,9538,6537,5584,9823,558
       Property Plant Equipment 
707
774
1,517
8,523
7,943
7,335
6,442
6,824
6,258
5,931
6,304
9,094
10,729
10,216
11,672
11,694
10,174
8,542
8,54210,17411,69411,67210,21610,7299,0946,3045,9316,2586,8246,4427,3357,9438,5231,517774707
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
-40,997
-40,99721000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
272
84
33,243
32,975
60,469
35,181
37,005
38,934
39,878
35,119
35,11939,87838,93437,00535,18160,46932,97533,2438427200000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
5,362
9,732
9,075
46,192
84,529
96,967
46,288
44,190
42,553
42,55344,19046,28896,96784,52946,1929,0759,7325,362000000000
       Long-term Assets Other 
2,851
4,208
6,041
130
10
11
692
0
2
84
0
355
111
87
16,826
30,087
29,969
14,248
14,24829,96930,08716,826871113550842069211101306,0414,2082,851
> Total Liabilities 
4,702
12,886
13,547
19,521
17,097
14,494
33,484
24,931
15,596
16,064
233,889
195,408
169,067
283,976
183,945
151,448
160,056
153,712
153,712160,056151,448183,945283,976169,067195,408233,88916,06415,59624,93133,48414,49417,09719,52113,54712,8864,702
   > Total Current Liabilities 
2,260
10,037
10,546
12,819
9,265
7,374
15,494
15,364
9,278
10,775
60,163
76,441
73,909
196,737
121,822
46,694
79,886
41,338
41,33879,88646,694121,822196,73773,90976,44160,16310,7759,27815,36415,4947,3749,26512,81910,54610,0372,260
       Short-term Debt 
169
585
0
0
723
701
13,221
1,178
613
453
622
1,264
1,343
1,347
2,130
2,142
30,748
2,102
2,10230,7482,1422,1301,3471,3431,2646224536131,17813,22170172300585169
       Short Long Term Debt 
0
0
0
0
0
0
0
0
4,819
4,206
150
375
429
394
1,493
2,142
30,748
1,263
1,26330,7482,1421,4933944293751504,2064,81900000000
       Accounts payable 
1,341
2,896
9,670
9,721
8,369
6,660
0
4,670
5,141
6,846
59,541
15,599
19,970
41,676
27,936
29,539
28,573
20,911
20,91128,57329,53927,93641,67619,97015,59959,5416,8465,1414,67006,6608,3699,7219,6702,8961,341
       Other Current Liabilities 
750
6,556
876
3,098
173
13
2,273
1,853
2,265
5,182
50,923
4,666
9,374
71,618
42,986
2,508
8,065
11,765
11,7658,0652,50842,98671,6189,3744,66650,9235,1822,2651,8532,273131733,0988766,556750
   > Long-term Liabilities 
2,442
2,849
3,001
6,702
7,832
7,120
17,990
9,567
6,318
5,289
173,726
118,967
95,158
87,239
62,123
104,754
80,170
112,374
112,37480,170104,75462,12387,23995,158118,967173,7265,2896,3189,56717,9907,1207,8326,7023,0012,8492,442
       Other Liabilities 
0
0
0
0
0
0
0
0
2,112
1,536
170,594
114,904
90,637
84,064
45,530
89,014
66,667
72,225
72,22566,66789,01445,53084,06490,637114,904170,5941,5362,11200000000
> Total Stockholder Equity
20,065
56,369
49,606
41,341
47,122
33,516
26,625
23,364
40,286
74,626
72,067
86,169
85,956
167,240
217,416
155,975
107,440
54,151
54,151107,440155,975217,416167,24085,95686,16972,06774,62640,28623,36426,62533,51647,12241,34149,60656,36920,065
   Common Stock
745
1,249
1,259
1,296
1,832
1,884
1,884
1,897
2,287
2,648
2,692
2,696
2,880
3,197
3,941
3,950
3,978
4,011
4,0113,9783,9503,9413,1972,8802,6962,6922,6482,2871,8971,8841,8841,8321,2961,2591,249745
   Retained Earnings -330,316-272,213-220,460-155,671-134,791-151,980-103,595-116,231-109,528-89,964-87,069-6,980-76,883-63,223-44,060-34,461-26,145-19,769
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
39,089
81,265
82,808
84,105
108,294
108,174
31,721
108,553
128,001
181,747
186,336
187,571
234,876
299,933
369,618
372,130
375,219
379,637
379,637375,219372,130369,618299,933234,876187,571186,336181,747128,001108,55331,721108,174108,29484,10582,80881,26539,089



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue49,639
Cost of Revenue-51,663
Gross Profit-2,024-2,024
 
Operating Income (+$)
Gross Profit-2,024
Operating Expense-66,064
Operating Income-57,425-68,088
 
Operating Expense (+$)
Research Development51,663
Selling General Administrative14,473
Selling And Marketing Expenses7,963
Operating Expense66,06474,099
 
Net Interest Income (+$)
Interest Income4,775
Interest Expense-5,321
Other Finance Cost-0
Net Interest Income-546
 
Pretax Income (+$)
Operating Income-57,425
Net Interest Income-546
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-57,972-16,425
EBIT - interestExpense = -16,972
-52,651
-52,782
Interest Expense5,321
Earnings Before Interest and Taxes (EBIT)-11,651-52,651
Earnings Before Interest and Taxes (EBITDA)33,754
 
After tax Income (+$)
Income Before Tax-57,972
Tax Provision-0
Net Income From Continuing Ops-57,972-57,972
Net Income-58,103
Net Income Applicable To Common Shares-58,103
 
Non-recurring Events
Discontinued Operations-131
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses66,064
Total Other Income/Expenses Net-41,000546
 

Technical Analysis of Innate Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Innate Pharma. The general trend of Innate Pharma is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Innate Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Innate Pharma.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.395 < 2.44 < 2.55.

The bearish price targets are: 2.44 > 2.299 > 2.185.

Tweet this
Innate Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Innate Pharma. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Innate Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Innate Pharma. The current macd is -0.0859358.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Innate Pharma price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Innate Pharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Innate Pharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Innate Pharma Daily Moving Average Convergence/Divergence (MACD) ChartInnate Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Innate Pharma. The current adx is 75.77.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Innate Pharma shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Innate Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Innate Pharma. The current sar is 2.3405.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Innate Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Innate Pharma. The current rsi is 54.10. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Innate Pharma Daily Relative Strength Index (RSI) ChartInnate Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Innate Pharma. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Innate Pharma price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Innate Pharma Daily Stochastic Oscillator ChartInnate Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Innate Pharma. The current cci is 24.46.

Innate Pharma Daily Commodity Channel Index (CCI) ChartInnate Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Innate Pharma. The current cmo is 28.24.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Innate Pharma Daily Chande Momentum Oscillator (CMO) ChartInnate Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Innate Pharma. The current willr is -22.61712439.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Innate Pharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Innate Pharma Daily Williams %R ChartInnate Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Innate Pharma.

Innate Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Innate Pharma. The current atr is 0.03735765.

Innate Pharma Daily Average True Range (ATR) ChartInnate Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Innate Pharma. The current obv is -27,700.

Innate Pharma Daily On-Balance Volume (OBV) ChartInnate Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Innate Pharma. The current mfi is 68.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Innate Pharma Daily Money Flow Index (MFI) ChartInnate Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Innate Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-17MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Innate Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Innate Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.100
Ma 20Greater thanMa 502.501
Ma 50Greater thanMa 1002.704
Ma 100Greater thanMa 2002.628
OpenGreater thanClose2.390
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Innate Pharma with someone you think should read this too:
  • Are you bullish or bearish on Innate Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Innate Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Innate Pharma

I send you an email if I find something interesting about Innate Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about Innate Pharma.

Receive notifications about Innate Pharma in your mailbox!